NCCN Small Cell Lung Cancer Panel Members

* Gregory P. Kalemkerian, MD/Chair †
  University of Michigan Comprehensive Cancer Center

Wallace Akerley, MD †
Huntsman Cancer Institute at the University of Utah

Robert J. Downey, MD ¶
Memorial Sloan-Kettering Cancer Center

David S. Ettinger, MD †
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Frank Fossella, MD †
The University of Texas M. D. Anderson Cancer Center

John C. Grecula, MD §
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute at The Ohio State University

Thierry Jahan, MD †
UCSF Comprehensive Cancer Center

Bruce E. Johnson, MD/Chair †
Dana-Farber/Partners CancerCare

Anne Kessinger, MD †
UNMC Eppley Cancer Center at The Nebraska Medical Center

Marianna Koczywas, MD †
City of Hope Cancer Center

Corey J. Langer, MD †
Fox Chase Cancer Center

Renato Martins, MD †
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Harvey B. Niell, MD †
St. Jude Children's Research Hospital/University of Tennessee Cancer Institute

Nithya Ramnath, MD †
Roswell Park Cancer Institute

Neal Ready, MDiv, PhD
Duke Comprehensive Cancer Center

Francisco Robert, MD †
University of Alabama at Birmingham Comprehensive Cancer Center

Charles C. Williams, Jr., MD †
H. Lee Moffitt Cancer Center and Research Institute at the University of South Florida

† Medical Oncology
¶ Surgery/Surgical oncology
§ Radiation oncology/Radiotherapy
* Writing Committee Member

Continue
Table of Contents

**NCCN Small Cell Lung Cancer Panel Members**

Small Cell Lung Cancer:
- Initial Evaluation and Staging (SCL-1)
- Limited Stage, Workup and Treatment (SCL-2)
- Extensive Stage, Workup and Treatment (SCL-4)
- Response Assessment after Initial Therapy (SCL-5)
- Surveillance (SCL-5)
- Subsequent Therapy and Palliative Therapy (SCL-6)
- Principles of Surgical Resection (SCL-A)
- Principles of Chemotherapy (SCL-B)
- Principles of Radiation Therapy (SCL-C)
- Principles of Supportive Care (SCL-D)

Lung Neuroendocrine Tumors:
- Workup and Primary Treatment (LNT-1)
  - NSCLC with neuroendocrine features or Large-cell neuroendocrine tumor
  - Carcinoid
  - Atypical carcinoid
  - Combined SCLC and NSCLC

Guidelines Index
Print the Small Cell Lung Cancer Guideline

These guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representations nor warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. These guidelines are copyrighted by National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2007.
Summary of the Guidelines updates

Summary of the changes in the 1.2007 version of the Small Cell Lung Cancer Guidelines from the 1.2006 version include:

- In the Initial Evaluation, "optional" was added to the chest x-ray recommendation (SCL-1).
- Footnote "f" was clarified that if an effusion is too small to allow image-guided sampling, it should not be considered in staging (SCL-2).
- Endoscopic staging was added as an option to mediastinal staging with new footnote "i" that if the results are positive, additional mediastinal staging would not be required (SCL-2).
- A category was added for patients with a Performance Status 3-4 not due to SCLC with the treatment recommendation of "Individualized therapy including supportive care regimens" (SCL-3).
- Second-line therapy was changed to "Subsequent therapy" (SCL-6).
- Principles of Surgical Resection - the option for endoscopic staging was added to bullet 4 (SCL-A).
- Principles of Radiation Therapy - the statement regarding the recommendation for lower fraction regimens was added to the PCI dosing section (SCL-C).
- Lung Neuroendocrine Tumors - the category designation was changed to 2A for an octreotide scan for atypical carcinoid and carcinoid tumors (LNT-1).
- The AJCC Staging (6th Edition) was added to the Staging section (ST-1).
# Small Cell Lung Cancer

**DIAGNOSIS**

Small cell or combined Small cell/Non-small cell lung cancer on biopsy or cytology of primary or metastatic site

**INITIAL EVALUATION**

- H&P
- Pathology review
- Chest x-ray (optional)
- Chest/liver/adrenal CT
- Head MRI (preferred) or CT\(^b\)
- Bone scan
- CBC, platelets
- Electrolytes, liver function tests (LFT), Ca, LDH
- BUN, creatinine
- PET scan (optional)\(^c\)
- Smoking cessation counseling and intervention

**STAGE**

- Limited stage
  - See Additional Workup (SCL-2)
- Extensive stage
  - See Additional Workup (SCL-4)

---

\(^a\) If extensive stage is established, further testing for staging is optional.

\(^b\) Head MRI is more sensitive than CT for identifying brain metastases and is preferred over CT.

\(^c\) PET scan can be used as part of the initial evaluation, in addition to the other recommended studies.

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### STAGE ADDITIONAL WORKUP

**Limited stage**
- Unilateral marrow aspiration/biopsy in select patients\(^e\)
- If pleural effusion is seen in chest x-ray, thoracentesis is recommended, if thoracentesis inconclusive, consider thoracoscopy\(^f\)
- Pulmonary function tests (PFTs) (if clinically indicated)
- Bone radiographs of areas showing abnormal uptake on bone scan
- MRI of bony lesions, if x-rays negative or inconclusive

**Clinical stage T1-2, N0**
- PET scan\(^g\)

**Limited disease in excess of T1-T2, N0**
- Bone marrow biopsy, thoracentesis, or bone studies consistent with malignancy

**Mediastinoscopy\(^h\) or Surgical or endoscopic\(^i\) mediastinal staging\(^h\)**

**Follow Pathway For Extensive-Stage Disease (See SCL-4)**

---

\(^e\) Selection criteria include: nucleated RBCs on peripheral blood smear, neutropenia, or thrombocytopenia.

\(^f\) Most pleural effusions in patients with lung cancer are due to cancer; however, if the effusion is too small to allow image-guided sampling, then the effusion should not be considered in staging. If multiple cytological examinations of pleural fluid are negative for cancer, fluid is not bloody and not an exudate and clinical judgment suggests that the effusion is not directly related to the cancer, then the effusion should not be considered in staging.

\(^g\) PET scan to identify distant disease and to guide mediastinal evaluation.

\(^h\) See Principles of Surgical Resection (SCL-A).

\(^i\) If endoscopic lymph node biopsy is positive, additional mediastinal staging is not required.
INITIAL TREATMENT

**TESTING RESULTS**

**Clinical stage T1-2, N0**
- Mediastinoscopy or mediastinal staging negative
  - Lobectomy (preferred) and mediastinal lymph node dissection or sampling
    - N0 → Chemotherapy
    - N+ → Concurrent chemotherapy + mediastinal RT

- Mediastinoscopy or mediastinal staging positive
  - Good performance status
    → Chemotherapy + concurrent thoracic RT (category 1)
  - Poor performance status due to SCLC
    → Chemotherapy ± RT
  - Performance status (PS) 3-4 not due to SCLC
    → Individualized treatment including supportive care regimens

**Limited disease in excess of T1-2, N0**
- Good performance status
  → Chemotherapy + concurrent RT (category 1)
- Poor performance status due to SCLC
  → Chemotherapy ± RT
- Performance status (PS) 3-4 not due to SCLC
  → Individualized treatment including supportive care regimens

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

See Principles of Surgical Resection (SCL-A), See Principles of Chemotherapy (SCL-B), See Principles of Radiation Therapy (SCL-C), See Principles of Supportive Care (SCL-D).
Small Cell Lung Cancer

STAGE | ADDITIONAL WORKUP | INITIAL TREATMENT
--- | --- | ---

### Extensive stage
- **Plain-film x-rays of bone scan abnormalities of weight-bearing areas**

#### Extensive stage without localized symptomatic sites or brain metastases
- **Performance status (PS) 3-4**
- **Severely debilitated**

**Combination chemotherapy** including supportive care regimens

**See NCCN Palliative Care Guidelines**

#### Extensive stage with localized symptomatic sites
- **SVC syndrome**
- **Lobar obstruction**
- **Bone metastases**

**Chemotherapy** ± symptomatic field RT

**For management of osseous structural impairment,**

**See NCCN Bone Cancers Guidelines**

#### Extensive stage with brain metastases
- **Spinal cord compression**

**Whole-brain RT followed by chemotherapy,** unless immediate systemic therapy is required
- **If asymptomatic, may administer RT after chemotherapy is initiated.**

**See NCCN CNS Tumors Guidelines**

---

1. See Principles of Chemotherapy (SCL-B).
2. See Principles of Supportive Care (SCL-D).
3. Sequential radiotherapy to thorax in selected patients with low-bulk metastatic disease and CR or near CR after systemic therapy.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**RESPONSE ASSESSMENT FOLLOWING INITIAL THERAPY**

- Complete response or radiation scarring or \( \leq 10\% \) of original mass on CT scan
- Partial response
- Primary progressive disease

**ADJUVANT TREATMENT**

- Limited disease: PCI\(^k,n\) (category 1)
- Extensive disease: PCI\(^k,n\) (category 2B)

**SURVEILLANCE**

- After recovery from primary therapy:
  - Oncology follow-up visits every 2-3 mo during y 1, every 3-4 mo during y 2-3, every 4-6 mo during y 4-5, then annually
  - At every visit: H&P, chest imaging, bloodwork as clinically indicated
  - New pulmonary nodule after 2 y follow-up should initiate workup for potential new primary
  - Smoking cessation intervention

\(^k\) See Principles of Radiation Therapy (SCL-C).

\(^n\) Not recommended in patients with multiple comorbidities, poor performance status, or impaired mental function.
PROGRESSIVE DISEASE  

SUBSEQUENT THERAPY/PALLIATION

Relapse

- Subsequent chemotherapy
  - or Clinical trial
  - or Best supportive care

- Continue until maximal benefit or refractory to therapy or development of unacceptable toxicity

- Clinical trial or Best supportive care

Primary progressive disease

- Palliative symptom management, including localized RT
  - or Clinical trial
  - or Subsequent chemotherapy (PS 0–2)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

See Principles of Chemotherapy (SCL-B).
PRINCIPLES OF SURGICAL RESECTION

- Stage I SCLC is diagnosed in less than 5% of patients with SCLC.
- Patients with clinically staged disease in excess of T1-2, N0 do not benefit from surgery.¹
- Patients with SCLC that is clinical stage I (T1-2, N0) after standard staging evaluation (including CT of the chest and upper abdomen, bone scan, brain imaging, and PET imaging) may be considered for surgical resection.
  - Prior to resection, all patients should undergo mediastinoscopy or other surgical mediastinal staging to rule out occult nodal disease. This may also include an endoscopic staging procedure.
  - Patients who undergo complete resection (preferably by a lobectomy with either mediastinal nodal dissection or sampling) should be treated with postoperative chemotherapy. Patients without nodal metastases should be treated with chemotherapy alone. Patients with nodal metastases may be considered for postoperative radiation therapy.
- Because prophylactic cranial irradiation (PCI) can improve both disease-free and overall survival in patients with SCLC in complete remission, PCI should be considered after adjuvant chemotherapy in patients who have undergone a complete resection.²

Chemotherapy as primary therapy:
- Limited stage:
  - Cisplatin: 60 mg/m² day 1 and Etoposide: 120 mg/m² days 1, 2, 3 x 4 cycles¹
  - Carboplatin: AUC 5-6 day 1 and Etoposide: 100 mg/m² days 1, 2, 3 x 4 cycles²
- During chemotherapy + RT, cisplatin/etoposide is recommended (category 1)

- Extensive stage:
  - Cisplatin: 75 mg/m² day 1 and Etoposide: 100 mg/m² days 1, 2, 3 x 4-6 cycles³
  - Carboplatin: AUC 5-6 day 1 and Etoposide: 100 mg/m² days 1, 2, 3 x 4-6 cycles²
  - Irinotecan: 60 mg/m² on days 1, 8, 15 and Cisplatin: 60 mg/m² on day 1⁴
  - Cisplatin 80 mg/m² day 1 and etoposide 80 mg/m² days 1, 2, 3⁵
  - Cisplatin 25 mg/m² days 1, 2, 3 and etoposide 100 mg/m² days 1, 2, 3⁶
  - Cyclophosphamide 1000 mg/m² day 1 and doxorubicin 45 mg/m² day 1 and vincristine 1.4 mg/m² day 1⁷
  - Cyclophosphamide 1000 mg/m² day 1 and doxorubicin 45 mg/m² day 1 and etoposide 100 mg/m² days 1, 2, 3⁸

Subsequent chemotherapy:
- Clinical trial preferred.
- Relapse < 2-3 mo, PS 0-2: ifosfamide, paclitaxel, docetaxel, gemcitabine.
- Relapse > 2-3 mo up to 6 mo: topotecan (category 1), irinotecan, cyclophosphamide/doxorubicin/vincristine (CAV), gemcitabine, taxane, oral etoposide, vinorelbine.
- Relapse > 6 mo: original regimen.

Consider dose reductions versus growth factors in the poor performance status patient

*The regimens included are representative of the more commonly used regimens for Small Cell Lung Cancer.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
PRINCIPLES OF CHEMOTHERAPY

References


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**PRINCIPLES OF RADIATION THERAPY**

Radiotherapy for limited disease:
- Radiotherapy should be delivered as either 1.5 Gy bid to a total dose of 45 Gy, or 1.8-2.0 Gy once daily to 50-60 Gy.\(^1,2,3,4\)
- Start with chemotherapy cycle 1 or 2 (category 1)
- The radiation target volumes should be defined on the CT scan obtained at the time of radiotherapy planning. However, the pre-chemotherapy CT scan should be reviewed to include the originally involved lymph node regions in the treatment fields.\(^5,6\)
- Concurrent chemoradiotherapy preferable to sequential therapy in fit patients (category 1)
- PCI dose 25-36 Gy (30 Gy in 15 fractions, 36 Gy in 18 fractions, or 25 Gy in 10 fractions)\(^7,8\)

Lower fraction regimens are recommended (1.8-2.0 Gy/fraction).

---

PRINCIPLES OF SUPPORTIVE CARE

- Smoking cessation counseling
- Granulocyte colony-stimulating factor (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) during RT is not recommended (category 1 for GMSCF). See the NCCN Myeloid Growth Factor Guidelines
- Syndrome of inappropriate antidiuretic hormone
  - Fluid restriction
  - Saline infusion for symptomatic patients
  - Demeclocycline
  - Antineoplastic therapy
- Cushing’s syndrome
  - Consider ketoconazole
  - Try to control before initiation of antineoplastic therapy
- Leptomeningeal disease
  See NCCN Carcinomatous/Lymphomatous Meningitis Guidelines
- Pain Management: See NCCN Adult Cancer Pain Guidelines
- Nausea/Vomiting: See NCCN Antiemesis Guidelines
- Psychosocial distress: See NCCN Distress Management Guidelines
- See NCCN Palliative Care Guidelines as indicated

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Lung Neuroendocrine Tumors**

### PATHOLOGIC ENTITY

- **NSCLC with neuroendocrine features or Large-cell neuroendocrine tumor**  
  - Treat per NCCN Non-Small Cell Lung Cancer Guidelines

- **Carcinoid**
  - Biopsy
  - Atypical Carcinoid
  - Combined SCLC and NSCLC  
  - Treat per NCCN Small Cell Lung Cancer Guidelines (see SCL-1)

### WORKUP

- **Stage I**
  - Chest/abdominal CT
  - Bronchoscopy
  - If enlarged mediastinal nodes on CT, mediastinoscopy or other mediastinal staging
  - Consider octreotide scan
  - PET scan (optional)

- **Stage II**
  - Surgery:
    - Lobectomy or other anatomic resection + mediastinal lymph node dissection or sampling

- **Stage IIIa**
  - Systemic therapy, consider octreotide if octreotide scan positive or symptoms of carcinoid syndrome

- **Stage IIIb, IV or unresectable**
  - Systemic therapy, consider octreotide if octreotide scan positive or symptoms of carcinoid syndrome

### CLINICAL STAGE/TREATMENT

- **Stage I**
  - Typical → I, II, III → Observe

- **Stage II**
  - Typical → I, II, III → Observe

- **Stage IIIa**
  - Typical → I, II, III → Observe

- **Stage IIIb, IV or unresectable**
  - Typical → I, II, III → Observe

### PATHOLOGY

- **Typical**
  - Surgery:
    - Lobectomy or other anatomic resection + mediastinal lymph node dissection or sampling

- **Atypical**
  - Chemo-therapy (category 2B)

### ADJUVANT TREATMENT

- **I**
  - Observe

- **II, III**
  - Observe

- **Combined SCLC and NSCLC**
  - Treat per NCCN Small Cell Lung Cancer Guidelines (see SCL-1)

---

**a** Management of endocrine symptoms as indicated (See the Carcinoid Tumors section in the NCCN Neuroendocrine Tumors Guidelines)

**b** PET scan is undergoing evaluation in clinical trials and should only be considered as a supplement and not a replacement to other studies.

**c** For Stage III, typical: RT recommended if surgery is not feasible.

For Stage III, atypical: Chemotherapy/RT is recommended if surgery is not feasible.

**d** There is no substantial evidence for a commonly used regimen. Cisplatin/etoposide is a regimen commonly used at NCCN institutions.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**Staging**

**Table 1 - Definition of Small cell lung cancer consists of two stages:**
(1) Limited-stage disease: disease confined to the ipsilateral hemithorax, which can be safely encompassed within a tolerable radiation field.
(2) Extensive-stage disease: disease beyond ipsilateral hemithorax which may include malignant pleural or pericardial effusion or hematogenous metastases.

**Table 2 - Revised Definition of TNM***

<table>
<thead>
<tr>
<th>Primary Tumor (T)</th>
<th>Regional Lymph Nodes (N)</th>
<th>Distant Metastasis (M)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</td>
<td>NX Regional lymph nodes cannot be assessed</td>
<td>MX Distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>T0 No evidence of primary tumor</td>
<td>N0 No regional lymph node metastasis</td>
<td>M0 No distant metastasis</td>
</tr>
<tr>
<td>Tis Carcinoma in situ</td>
<td>N1 Metastasis to ipsilateral peribronchial and/or ipsilateral hilar lymph nodes, and intrapulmonary nodes including involvement by direct extension of the primary tumor</td>
<td>M1 Distant metastasis present§</td>
</tr>
<tr>
<td>T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus† (ie, not in the main bronchus)</td>
<td>N2 Metastasis to ipsilateral mediastinal and/or subcarinal lymph node(s)</td>
<td></td>
</tr>
<tr>
<td>T2 Tumor with any of the following features of size or extent: More than 3 cm in greatest dimension Invades main bronchus, 2 cm or more distal to the carina Invades the visceral pleura Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung</td>
<td>N3 Metastasis to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td>
<td></td>
</tr>
<tr>
<td>T3 Tumor of any size that directly invades any of the following: chest wall (including superior sulcus tumors), diaphragm, mediastinal pleura, parietal pericardium; or tumor in the main bronchus less than 2 cm distal to the carina, but without involvement of the carina; or associated atelectasis or obstructive pneumonitis of the entire lung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4 Tumor of any size that invades any of the following: mediastinum, heart, great vessels, trachea, esophagus, vertebral body, carina; or separate tumor nodules in the same lobe; or tumor with a malignant pleural effusion‡</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Most pleural effusions associated with lung cancer are due to tumor. However, in a few patients, multiple cytopathologic examinations of pleural fluid are negative for tumor. In these cases, fluid is not bloody and is not an exudate. Such patients may be further evaluated by videothoracoscopy (VATS) and direct pleural biopsies. When these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging element and the patient should be staged T1, T2, or T3.

§ M1 includes separate tumor nodule(s) in a different lobe (ipsilateral or contralateral).

*Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original and primary source for this information is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York. (For more information, visit www.cancerstaging.net.) Any citation or quotation of this material must be credited to the AJCC as its primary source. The inclusion of this information herein does not authorize any reuse or further distribution without the expressed, written permission of Springer-Verlag New York, Inc., on behalf of the AJCC.
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers. In 2005, approximately 26,000 new cases of SCLC will be diagnosed in the United States. Most cases of SCLC are attributable to cigarette smoking, whereas the remaining cases are presumably caused by environmental or genetic factors. When compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. Approximately 67% of patients with SCLC present with overt, metastatic disease outside the chest, whereas only 33% of patients present with limited disease confined to the chest within a single radiation port. SCLC is highly sensitive to initial chemotherapy and radiotherapy; however, most patients eventually die from recurrent disease. Treatment using chemotherapy plus chest radiotherapy can be curative for some patients with limited-stage SCLC, while chemotherapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Surgery is appropriate for the few patients (2%-5%) with surgically resectable SCLC.

Pathology

SCLC is a malignant epithelial tumor consisting of small cells with scant cytoplasm, ill-defined cell borders, finely granular nuclear chromatin, and absent or inconspicuous nucleoli. The cells are round, oval, or spindle shaped, and nuclear molding is prominent. The mitotic count is high. Up to 30% of autopsies in patients with SCLC have areas of non-small cell carcinoma differentiation, which are less commonly detected in specimens from previously untreated patients. This finding has led to the proposal that pulmonary carcinogenesis occurs in a pluripotent stem cell capable of differentiation along several pathways.

The differential diagnosis of small blue tumors includes SCLC, extrapulmonary small cell carcinoma, Merkel cell tumors, carcinoid tumors, atypical carcinoid tumors, large cell neuroendocrine carcinoma, lymphoma, small cell sarcomas, and other neuroendocrine tumors. Small cell carcinomas can also originate in extrapulmonary sites, including the nasopharynx, gastrointestinal tract, and genitourinary tract. Both pulmonary and extrapulmonary small cell carcinomas have a similar clinical and biologic behavior, leading to a high potential for widespread metastases. However, unlike SCLC, malignant cells from patients with extrapulmonary small cell carcinoma do not exhibit macromolecular 3p deletions, which suggests a different pathogenesis.
Nearly all SCLCs are immunoreactive for keratin, epithelial membrane antigen, and thyroid transcription factor 1 (TTF1). Many SCLCs also stain positively for markers of neuroendocrine differentiation, including chromogranin A, neuron-specific enolase, neural cell adhesion molecule (NCAM), and synaptophysin. However, these markers alone cannot be used to distinguish SCLC from non-small cell lung cancer, because approximately 10% of non-small cell lung cancers will be immunoreactive for at least one of these neuroendocrine markers.9

Many neurologic and endocrine paraneoplastic syndromes are associated with SCLC. These neurologic syndromes include Lambert-Eaton myasthenic syndrome, encephalomyelitis, and sensory neuropathy. The Lambert-Eaton syndrome presents with proximal leg weakness and is caused by antibodies directed against the voltage-gated calcium channels.10 Paraneoplastic encephalomyelitis and sensory neuropathy are caused by the production of an antibody (anti-Hu) that cross-reacts with both small cell carcinoma antigens and human neuronal RNA-binding proteins resulting in multiple neurologic deficits.11,12 SCLC cells also can produce numerous polypeptide hormones, including adrenocorticotropic hormone (ACTH) and vasopressin (ADH), which cause Cushing's syndrome and hyponatremia of malignancy, respectively.13,14

Clinical Manifestations, Staging, and Prognostic Factors

SCLC typically presents as a large hilar mass and bulky mediastinal lymphadenopathy that cause cough and dyspnea. Frequently, patients present with symptoms of widespread metastases, such as weight loss, debility, bone pain, and neurologic compromise. Presentation as a solitary peripheral nodule without central adenopathy is uncommon, and, in this situation, fine-needle aspiration may not adequately differentiate small cell carcinoma from typical or atypical carcinoid tumor or from large cell neuroendocrine carcinoma.

The Veteran's Administration Lung Group two-stage classification scheme is routinely used to define the extent of disease in patients with SCLC: (1) limited-stage disease is defined as disease confined to the ipsilateral hemithorax, which can be safely encompassed within a tolerable radiation field; and (2) extensive-stage disease is defined as disease beyond the ipsilateral hemithorax and may include malignant pleural or pericardial effusion or hematogenous metastases. Contralateral mediastinal and ipsilateral supraclavicular lymphadenopathy are generally classified as limited-stage disease, while contralateral hilar and supraclavicular lymphadenopathy usually are classified as extensive-stage disease. Approximately two-thirds of patients present with overt hematogenous metastases, which commonly involve the contralateral lung, liver, adrenal glands, brain, bones, and/or bone marrow.

All SCLC patients, even those with radiographically limited-stage disease, require systemic chemotherapy. Therefore, staging provides a therapeutic guideline for chest radiotherapy, which is indicated for patients with limited-stage disease but not typically for those with extensive-stage disease. Full staging includes a chest radiograph; physical examination; computed tomography (CT) scan including the chest, liver, and adrenal glands; a magnetic resonance imaging (MRI) scan (preferred) or CT scan of the head; and a bone scan. Unilateral or bilateral bone marrow aspirates and biopsies may be indicated in patients with cytopenias and no other evidence of metastatic disease. Bone marrow involvement as the only site of extensive-stage disease occurs in less than 5% of patients. A positron emission tomography (PET) scan can be used as part of
the initial evaluation in addition to the other recommended studies.

If a pleural effusion is large enough to be seen by a chest radiograph, then thoracentesis is recommended. If thoracentesis does not show malignant cells, then thoracoscopy can be considered to document pleural involvement and thus extensive-stage disease. A patient should be considered to have limited-stage disease if: (1) multiple cytopathologic examinations of pleural fluid are negative for cancer; (2) the fluid is not bloody and not an exudate; and (3) clinical judgment suggests that the effusion is not related to the cancer.

Staging should not be directed only to sites of symptomatic disease or sites suggested by laboratory tests. Bone scans are positive in up to 30% of patients without bone pain or an abnormal alkaline phosphatase level. A head MRI or CT scan can identify central nervous system (CNS) metastases in 10% to 15% of patients at diagnosis, of which about 30% are asymptomatic. Early treatment of brain metastases results in less chronic neurologic morbidity, arguing for the utility of early diagnosis in asymptomatic patients. Due to the aggressive nature of SCLC, staging should not delay the onset of treatment more than 1 to 2 weeks; otherwise, many patients may become more seriously ill in the interval with a decline in their performance status (PS).

Poor PS, extensive-stage disease, weight loss, and markers associated with excessive bulk of disease are the most important adverse prognostic factors. In patients with limited-stage disease, good PS, female gender, age younger than 70 years, normal LDH, and stage I disease are associated with a more favorable prognosis. In patients with extensive-stage disease, normal LDH and a single metastatic site are favorable prognostic factors.\(^{15,16}\)

### Chemotherapy

Chemotherapy is an essential component of appropriate treatment for all patients with SCLC.\(^4\) For those who have undergone successful surgical resection, adjuvant chemotherapy is recommended. For most patients with limited-stage SCLC, recommended treatment consists of chemotherapy with thoracic radiotherapy. For most patients with extensive-stage disease, combination chemotherapy is the recommended treatment.

Single-agent and combination chemotherapy regimens have been shown to be active in SCLC.\(^3,17,18\) The most commonly used initial combination chemotherapy regimen is etoposide and cisplatin (EP).\(^4\) This combination was developed based on the finding of preclinical synergy using cisplatin and etoposide, and it supplanted alkylator/anthracycline-based regimens based on superiority in both efficacy and toxicity in the limited-stage setting.\(^25\) EP plus concurrent thoracic radiotherapy is now the recommended therapy for patients with limited-stage disease (category 1). In combination with thoracic radiotherapy, EP causes an increased risk of esophagitis and pulmonary toxicity. The hematologic toxicity is manageable with dose reductions or growth factor support. In clinical practice, carboplatin is frequently substituted for cisplatin in order to reduce the risk of emesis, neuropathy, and nephropathy. However, the use of carboplatin carries a greater risk of myelosuppression.\(^21\) The substitution of carboplatin for cisplatin in patients with limited-stage disease has not been adequately evaluated and should only be done when cisplatin is contraindicated or poorly tolerated.\(^22\) The substitution of carboplatin for cisplatin is more acceptable in patients with extensive-stage disease, because chemotherapy is rarely curative in these patients.\(^22\)
Other combinations have been evaluated in patients with extensive-stage disease with little consistent evidence of benefit when compared with EP. A phase III trial performed in Japan reported that patients with extensive-stage SCLC who were treated with irinotecan plus cisplatin achieved a median survival of 12.8 months compared to 9.4 months for patients treated with EP ($P = .002$). In addition, 2-year survival was 19.5% in the irinotecan plus cisplatin group and 5.2% in the EP group. However, a larger trial with a similar design performed in the United States comparing irinotecan plus cisplatin to EP failed to demonstrate a significant difference in response rate or overall survival between the regimens.

In patients with limited-stage disease, response rates of 70% to 90% are expected after treatment with etoposide plus thoracic radiotherapy, while in extensive-stage disease, response rates of 60% to 70% can be achieved with combination chemotherapy alone. Unfortunately, median survival rates are only 14 to 20 months and 9 to 11 months for patients with limited-stage and extensive-stage disease, respectively. After appropriate treatment, the 2-year survival rate is about 40% in patients with limited-stage disease, but less than 5% in those with extensive-stage disease. Thoracic radiotherapy improves the local control rates by 25% in limited-stage disease patients and is associated with improved survival.

Many strategies have been evaluated in an effort to improve on the results that have been achieved with standard treatment for extensive-stage SCLC, including the addition of a third agent to standard two-drug regimens. In two trials, the addition of ifosfamide, or cyclophosphamide plus an anthracycline, to EP demonstrated a modest survival advantage for patients with extensive disease. However, such findings have not been uniformly observed, and the addition of ifosfamide with or without an anthracycline significantly increased hematologic toxicity when compared to EP alone. Similarly, the addition of paclitaxel to cisplatin or carboplatin plus etoposide yielded promising results in phase II trials but did not improve survival and was associated with unacceptable toxicity in a subsequent phase III study. The use of maintenance or consolidation chemotherapy beyond 4 to 6 cycles of standard treatment produces a minor prolongation of duration of response without improving survival and carries a greater risk of cumulative toxicity.

The inability to destroy residual cells despite initial chemosensitivity of SCLC suggests the existence of tumor stem cells that are relatively resistant to cytotoxic therapy. To overcome drug resistance, alternating or sequential combination therapies have been designed to expose the tumor to as many active cytotoxic agents as possible during initial treatment. However, randomized trials have failed to show improved disease-free or overall survival with this approach.

Multidrug cyclic weekly therapy was designed to increase the dose-intensity of treatment by taking advantage of the differing toxicities of the weekly agents. Although patient selection effects were of some concern, early phase II results were promising. Nevertheless, no survival benefits were documented in randomized trials and excessive treatment-related mortality was noted with multidrug cyclic weekly regimens.

The role of higher-dose therapy for patients with SCLC remains controversial. A meta-analysis was performed to assess whether the dose-intensity of individual agents or regimens correlated with response or survival in SCLC trials. This study evaluated trials in...
which the relative dose-intensities of the CAV, CAE, and EP regimens were analyzed over relatively narrow ranges. It found only a small, clinically insignificant enhancement of median survival in patients with extensive-stage disease when using increased relative dose-intensity.\textsuperscript{43}

Higher complete and partial response rates, as well as modestly longer median survival times, have been observed in patients receiving high doses when compared with those given conventional doses of the same agents.\textsuperscript{44} In general, however, randomized trials comparing an incremental dose-intensity between one and two times the full conventional dose have not consistently shown an increased response rate or survival advantage.\textsuperscript{45-48}

Currently available cytokines (eg, GM-CSF and G-CSF) can ameliorate chemotherapy-induced myelosuppression and reduce the incidence of febrile neutropenia, but cumulative thrombocytopenia remains dose-limiting. Although trials involving SCLC patients were instrumental in obtaining Food and Drug Administration (FDA) approval for the clinical use of cytokines,\textsuperscript{49} there is little evidence to suggest that maintenance of dose intensity prolongs disease-free or overall survival.

Overall, attempts to improve long-term survival rates in patients with SCLC through the addition of more agents or the use of dose-intense chemotherapy regimens, maintenance therapy, or alternating non-cross-resistant chemotherapy regimens have generally failed to yield significant advantages when compared to standard approaches.

**Elderly Patients**

The incidence of lung cancer increases with age; 66\% of patients with lung cancer are 65 years or older. However, elderly patients are under-represented in clinical trials.\textsuperscript{50} Although advanced chronological age adversely affects tolerance to treatment, an individual patient’s functional status is much more helpful in guiding clinical decision making. If an older person is functional in terms of the ability to perform activities of daily living, then the clear recommendation would be to treat this patient with the recommended combination chemotherapy (and radiotherapy, if indicated). Myelosuppression and fatigue as well as lower organ reserves may be encountered more frequently in elderly patients, particularly during the first cycle, because the toxicities of chemotherapy overlap with the adverse effects of the cancer.

Greater anticipation of the needs and support systems of elderly patients is recommended. However, elderly patients have similar prognoses when compared with younger patients. Randomized trials have indicated that less intensive treatment (eg, single-agent etoposide) is inferior to combination chemotherapy (such as platinum plus etoposide regimens) in elderly patients with good PS.\textsuperscript{51,52} Several other strategies have been evaluated in elderly patients with SCLC.\textsuperscript{53-55} The use of 4 cycles of carboplatin plus etoposide appears to yield favorable results, because the AUC (area-under-the-curve) dosing of carboplatin takes into account the declining renal function of the aging patient. However, some patients may not tolerate a dose of carboplatin with an AUC as high as 6.\textsuperscript{56} The utility of short-course, full-intensity chemotherapy has also been explored in elderly or infirm patients, and the results with only 2 cycles of chemotherapy appear to be quite acceptable.\textsuperscript{57} However, none of these newer approaches have been directly compared with standard therapy.

**Salvage Therapy**

Most patients with SCLC will relapse or progress after initial treatment; these patients have a median survival of only 4 to 5 months when treated with further chemotherapy. Second-line...
Chemotherapy provides significant palliation in many patients, although the likelihood of response is highly dependent on the time from last therapy to relapse. If this interval is less than 3 months, response to most agents or regimens is poor (10% or less), indicating refractory SCLC. If greater than 3 months has elapsed, expected response rates are approximately 25%. In phase II trials, active second-line agents include topotecan (category 1), irinotecan, paclitaxel, docetaxel, ifosfamide, oral etoposide, gemcitabine, and vinorelbine. In a randomized phase III trial, single-agent topotecan was compared to the combination regimen CAV (cyclophosphamide, doxorubicin [Adriamycin], and vincristine). Both arms had similar response rates and survival, but topotecan caused less toxicity and is now recommended as the second-line agent for patients with relapsed SCLC (category 1). Second-line chemotherapy should be given until patients achieve maximal benefit, become refractory to therapy, or develop unacceptable toxicity. For patients with localized symptomatic sites of disease (such as painful bony lesions, obstructive atelectasis, or brain metastases), radiotherapy can provide excellent palliation.

Radiotherapy

Thoracic Radiotherapy

The addition of thoracic radiotherapy has improved survival for patients with limited-stage disease. Meta-analyses that included more than 2000 patients show that thoracic radiation for limited-stage disease causes a 25% to 30% reduction in local failure and a corresponding 5% to 7% improvement in 2-year survival. However, achieving local control using conventional chemoradiotherapy for patients with limited-stage SCLC remains a challenge.

The administration of thoracic radiotherapy requires the assessment of several factors, including the timing of chemotherapy and radiotherapy (concurrent versus sequential versus alternating therapy), timing of radiotherapy (early versus late), volume of the radiation port (original tumor volume versus shrinking field as the tumor responds), dose of radiation, and fractionation of radiotherapy. A randomized trial by the Japanese Cooperative Oncology Group assessed sequential versus concurrent thoracic radiotherapy combined with EP for patients with limited-stage disease, and reported that patients treated with concurrent radiotherapy lived longer than those treated with sequential radiotherapy. Another randomized phase III trial by the National Cancer Institute of Canada compared radiotherapy beginning with either cycle 2 or cycle 6 of chemotherapy, and demonstrated that early radiotherapy was associated with improved local and systemic control and longer survival. A systematic review on the timing of thoracic radiotherapy in limited-stage SCLC determined that early concurrent radiotherapy results in a small, but significant, improvement in overall survival when compared to late concurrent or sequential radiotherapy.

Based on a phase II study by Turrisi et al, the Eastern Cooperative Oncology Group/Radiation Therapy Oncology Group (ECOG/RTOG) compared once a day to twice a day radiotherapy with EP. In this trial, 412 patients with limited-stage SCLC were treated with concurrent chemoradiotherapy using a total dose of 45 Gy delivered either twice a day over 3 weeks or once a day over 5 weeks. The twice-daily schedule produced a survival advantage along with a higher incidence of grade 3-4 esophagitis. Median survival was 23 versus 19 months ($P = .04$), and 5-year survival was 26% versus 16% in the twice-daily and once-daily radiotherapy arms, respectively.
A caveat to these encouraging long-term survival results is that twice-daily fractionation is technically challenging for patients with bilateral mediastinal adenopathy. In addition, the once-a-day therapy was not delivered at its maximum tolerated dose, so it remains unclear if hyperfractionation is superior to once daily chest radiotherapy given to a biologically equivalent dose. Another randomized phase III trial demonstrated no survival difference between once-a-day thoracic radiotherapy to 50.4 Gy with concurrent EP and a split-course of twice-a-day thoracic radiotherapy to 48 Gy with concurrent EP. However, split-course radiotherapy may be less efficacious because of interval tumor regrowth between courses. Overall, patients selected for combined modality treatment that incorporates twice-a-day radiotherapy must have an excellent PS and good baseline pulmonary function.

For limited-stage disease, the NCCN guidelines recommend that radiation should be delivered concurrently with chemotherapy and should start with the first or second cycle at a dose of either 1.5 Gy twice daily to a total dose of 45 Gy, or 1.8 Gy/day to at least 50 Gy. The radiation target volumes should be defined on the CT scan obtained at the time of radiotherapy planning. However, the pre-chemotherapy CT scan should be reviewed to include the originally involved lymph node regions in the treatment fields.

**Prophylactic Cranial Radiotherapy**

Intracranial metastases occur in more than 50% of patients with SCLC. Randomized studies have shown that prophylactic cranial irradiation (PCI) is effective in decreasing the incidence of cerebral metastases, but the individual studies did not have sufficient power to demonstrate a meaningful survival advantage. Moreover, late neurologic sequelae have been attributed to radiotherapy, particularly in studies using fractions greater than 3 Gy and/or administering PCI concurrent with chemotherapy. When given after the completion of chemotherapy and at low-doses per fractions, PCI may cause less neurological toxicity. Symptomatic brain relapses result in major morbidity, which frequently does not completely resolve with therapeutic cranial irradiation.

A meta-analysis of all randomized PCI trials reported a 25% decrease in the 3-year incidence of brain metastases from 58.6% in the control group to 33.3% in the PCI treated group. Thus, it appears that PCI prevents and does not simply delay the emergence of brain metastases. This meta-analysis also reported a 5.4% increase in 3-year survival in patients treated with PCI from 15.3% in the control group to 20.7% in the PCI group. Although the number of patients in this meta-analysis with extensive-stage disease was small, the observed benefit was similar in both limited- and extensive-stage patients.

A balanced discussion between the patient and physician is necessary before making a decision to administer PCI. On the basis of the meta-analysis, PCI is recommended for patients with limited-stage disease (category 1) who attain a complete response after initial chemoradiotherapy and can be used for patients with extensive-stage disease (category 2B) who achieve a complete response. PCI is not recommended for patients with multiple comorbidities, poor PS, or impaired mental function. Doses ranging from 25 Gy in 10 fractions to 36 Gy in 18 fractions are recommended. PCI should not be given concurrently with systemic chemotherapy because of the increased risk of neurotoxicity.

**Surgical Resection of Early-Stage SCLC**

Early-stage SCLC is diagnosed in less than 5% of patients with SCLC. Patients with clinically staged disease in excess of T1-2, N0...
do not benefit from surgery. The Lung Cancer Study Group conducted the only prospective randomized trial evaluating the role of surgery in SCLC.70 Patients with limited-stage disease, excluding those with stage I disease, received 5 cycles of chemotherapy with CAV. Patients demonstrating a response to chemotherapy were randomly assigned either to resection plus thoracic radiotherapy or to thoracic radiotherapy alone. The survival of patients on the two arms was equivalent, suggesting no benefit to surgery in this setting.

Patients with SCLC that has been determined to be clinical stage I (T1-2, N0) after a standard staging evaluation (including CT of the chest and upper abdomen, bone scan, brain imaging, and probably PET imaging) may undergo surgical resection.71 Before resection, all patients should undergo mediastinoscopy or other surgical mediastinal staging to rule out occult nodal disease.72 Patients who undergo complete resection (preferably by a lobectomy with either mediastinal nodal dissection or sampling) should be treated with postoperative chemotherapy.73,74 Patients without nodal metastases can be treated with chemotherapy alone, but concurrent chemotherapy and postoperative RT are recommended for patients with nodal metastases. Because PCI can improve both disease-free and overall survival in patients with SCLC in complete remission, it is reasonable to administer PCI after adjuvant chemotherapy in patients who have undergone a complete resection.66

SCLC can rarely be diagnosed during a thoracotomy performed for a pulmonary nodule that does not have a definitive diagnosis.75 In this situation, if intraoperative frozen section analysis suggests that all disease can be resected by a lobectomy with a nodal dissection even if nodal involvement is found, the recommendation (category 2B) is to complete the resection if the patient can tolerate the procedure. If the disease can only be resected by a pneumonectomy, then resection is rarely appropriate because of the greater operative mortality than with a lobectomy, the reduced tolerance for postoperative treatments, and the loss of pulmonary function, as well as the patient's overall medical condition. Postoperative therapy should then proceed as described earlier.

Management of Patients Not Participating in Clinical Trials

Clinical trials generally represent state-of-the-art treatment for patients with SCLC. Despite recent advances, the standard therapy for SCLC based on prior clinical trials and outlined by the practice guidelines does not yet result in very good outcomes. Thus, participation in clinical trials should be strongly encouraged.

Patients with limited-stage disease who are not enrolled in a clinical trial should be treated with concurrent chemotherapy (cisplatin plus etoposide for 4 cycles) plus early thoracic radiotherapy (category 1).61 Chest radiotherapy should begin during cycle 1 or 2 and should provide at least a biologically equivalent dose of 45 Gy in daily fractions of 1.8 Gy or greater (category 1).61,62 PCI is recommended for patients who achieve a complete response. Follow-up examinations are recommended every 2 to 3 months over the first several years with concomitant chest radiographs. Smoking cessation should be encouraged, because patients who smoke have increased toxicity during treatment and shorter survival.76 If a new pulmonary nodule appears after 2 years, it should be evaluated as a new primary tumor, because second primary tumors are a frequent occurrence in patients who are cured of SCLC.76

For patients with extensive-stage disease, standard combination
platinum-based chemotherapy is recommended, recognizing that new approaches are desperately needed.

Disclosures for the NCCN Small Cell Lung Cancer Guidelines Panel

At the beginning of each panel meeting to develop NCCN guidelines, panel members disclosed the names of companies, foundations, and/or funding agencies from which they received research support; for which they participate in speakers’ bureau, advisory boards; and/or in which they have equity interest or patents. Members of the panel indicated that they have received support from the following: Allos Therapeutics, Inc; Amgen; AstraZeneca; Bristol-Myers Squibb; Eli Lilly; Genentech Inc; GlaxoSmithKline; ImClone Systems Inc; Novartis Pharmaceuticals; Pfizer Inc; PharmacYclics Inc; and Sanofi-Aventis. Some panel members do not accept any support from industry. The panel did not regard any potential conflicts of interest as sufficient reason to disallow participation in panel deliberations by any member.
References


